RxDoctor Payments Data

Phillip Sandoval, MD

Internal Medicine · Albuquerque, NMNPI 1427123033

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 20 payments — averaging $56.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$471
  • Viiv Healthcare Company$203
  • Johnson & Johnson$143
  • Pharmaessentia USA Corporation$117
  • Novo Nordisk$103
  • E.r. Squibb & Sons, L.L.C.$83
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 85th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$32,652
Medicare patients
123
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$58,761
EliquisApixaban26$18,166
JanuviaSitagliptin Phosphate21$17,005
JardianceEmpagliflozin15$12,762
Repatha SureclickEvolocumab13$7,026
OxycontinOxycodone Hcl12$5,663
BrilintaTicagrelor11$4,981
Arnuity ElliptaFluticasone Furoate16$4,081
Oxycodone Hcl159$3,280
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,650
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,551
Fentanyl12$2,487
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$2,182
Albuterol Sulfate HfaAlbuterol Sulfate57$1,960
Potassium Chloride34$1,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$103$58,76155 claims
MerckJanuvia$16$17,00521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →